PACAP (1-38)
Nootropic / cognitive
Cognition, mood, neuroprotection, or neuroplasticity support
Reference-only summary of publicly discussed or source-listed patterns. Not medical advice and not a personal recommendation.
Mechanism & Use
- Compound type
- Nootropic / neuroactive compound
- Primary mechanism
- Neurotransmitter, neurotrophic, or plasticity pathway modulation
- Primary market use
- Nootropic / cognitive
Pharmacology
- Molecular weight (Da)
- 4534.26 | 4535.24
- Oral bioavailability
- Route-dependent / verify
- Half-life
- ~2–12 h small-molecule class estimate
- Route tags
- Route-dependent / verify
- Evidence level
- MCE product listing / research chemical signal
- Clinical status
- Research chemical/reference listing
- Value-for-money score
- 7 / 10
Reported protocol signal
No popular protocol verified yet; keep as reference compound until protocol signal is added.
For orientation only. See disclaimer — always consult a licensed clinician before use.
Stackability
Place in nootropic comparison clusters; track acute vs durable cognitive adaptation.
Notes
(1-38), human, ovine, rat is a PAC 1 receptor agonist. PACAP (1-38), human, ovine, rat binds to PACAP type I receptor, PACAP type II receptor VIP1, and PACAP type II receptor VIP2 with IC 50 s of 4 nM, 2 nM, and 1 nM, respectively. PACAP (1-38), human, ovine, rat increases the α-secretase activity. PACAP (1-38), human, ovine, rat elevates cytosolic Ca 2+ , increases proliferation and increases phosphorylation of extracellular regulates kinase ( ERK ) and the epidermal growth factor receptor ( EG...